Qiagen stock: buy or sell?
October 18th, 2019
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. It offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions.
Should I buy Qiagen stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Qiagen stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Qiagen stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 15 ratings published for QGEN stock in the last month. The general sentiment of these ratings is bullish for QGEN stock, with 12 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-1||Goldman Sachs Group||n/a||Buy|
|2019-7-12||Exane BNP Paribas||Neutral||Outperform|
|2019-6-21||Goldman Sachs Group||n/a||Buy|
|2019-5-7||Goldman Sachs Group||n/a||Buy|
|2019-1-21||Jefferies Financial Group||n/a||Neutral|
Qiagen stock analysis
Qiagen shares grew 1.10% to $28.49 on Oct 18th.
Qiagen shares grew 1.10% to $28.49 on Oct/18. Since August when QGEN stock price broke down the SMA200d line, it slid $-9.23 per share (-24.47%). QGEN marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $32.43 would break this short term down trend and open possibilities for reversing this situation.
After sliding a bloodcurdling -19.46% in a week last week, Qiagen closed this week at $28.49 and climbed a cool 5.21%. This week broke a red streak of 4 weeks.
Since late July, when QGEN stock price broke down the 40-weeks moving avarage line, it slid $-9.80 per share (-25.59%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.
Qiagen stock price history
Qiagen IPO was on June 28th, 1996 at $1.93 per share1. Since then, QGEN stock surged a 1,376.20%, with a yearly average of 59.80%. If you had invested right after QGEN's IPO a $1,000 in Qiagen stock in 1996, it would worth $13,762.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Qiagen stock historical price chart
QGEN stock reached 52-week highs on April at $41.55, and all-time highs 2000-07-17 with a price of 58.18.
Qiagen stock price target is $43.30Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We detected 3 price targets for QGEN stock posted in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter publishing its last earnings report on May, Qiagen . As soon as we get its actual EPS from the earnings report, we will extend this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Qiagen annual turnover soared a nice 5.95% to $1,501.85 M dollars from $1,417.54 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) escalated a 9.83% to 12.68%. Qiagen fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Qiagen TTM sales up to were $1,158.28 and earnings $158.09 million USD. If we compare this TTM figures with the last reported annuality, we can review Qiagen business evolution since December 2018: Annual revenues up to , compared to lastest yearly report, plunged a frightening -22.88%. In contrast, profit margin (net income/sales) stayed steady at 12.68%.
|2013||$1,300 M||-||$69 M5.3%||-|
|2014||$1,345 M||3.44%||$117 M8.7%||68.86%|
|2015||$1,281 M||-4.74%||$127 M9.9%||8.98%|
|2016||$1,338 M||4.45%||$80 M6.0%||-36.74%|
|2017||$1,418 M||5.95%||$40 M2.8%||-49.76%|
|2018||$1,502 M||5.95%||$190 M12.7%||371.31%|
|TTM||$1,158 M||-22.88%||$158 M13.6%||-16.96%|
Quarterly financial resultsQiagen reported million in sales for 2019-Q1, a -100.00% decline compared to previous quarter. Reported quarter earnings marked M with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was 15.12%. When comparing turnover to same quarter last year, Qiagen sales marked a hair-raising decrease and collapsed a -100.00%.
|2017-Q1||$308 M||-||$18 M5.7%||-|
|2017-Q2||$349 M||13.42%||$14 M4.0%||-20.96%|
|2017-Q3||$364 M||4.29%||$48 M13.3%||247.56%|
|2017-Q4||$397 M||9.04%||$-40 M-10.0%||-181.87%|
|2018-Q1||$344 M||-13.43%||$32 M9.4%||-181.36%|
|2018-Q2||$377 M||9.79%||$37 M9.8%||14.00%|
|2018-Q3||$378 M||0.19%||$60 M16.0%||63.85%|
|2018-Q4||$403 M||6.68%||$61 M15.1%||1.04%|
Qiagen ownershipWhen you are planning to buy shares of a company, it's worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Qiagen, 2.76% of all outstanding shares are owned by its staff.
In case of Qiagen stock, 72.73% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for QGEN stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Qiagen:
|Market cap||$6.5 B||$69.8 B||$78.2 B||$2.6 B||$329.7 M|
|Total shares||226.5 M||270.0 M||8,730.0 M||37.6 M||57.4 M|
|Float shares||217.7 M||269.1 M||8,710.0 M||25.0 M||45.2 M|
|- Institutional holdings (%)||72.7%||87.5%||58.6%||86.9%||95.9%|
|- Insider holdings (%)||2.8%||0.3%||0.2%||2.8%||6.6%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, October 18th, 2019|
|Day range||$28.29 - $28.64|
|Average true range||$1.18|
|50d mov avg||$32.71|
|100d mov avg||$35.96|
|200d mov avg||$37.17|
Qiagen performanceTo better understand Qiagen performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Qiagen performance to Becton, Dickinson and, General Electric, Genomic Health, GenMark Diagnostics, Hologic, Bio-Techne and Thermo Fisher Scientific:
|TMOThermo Fisher Sci...||-2.84%||8.47%||24.23%|